These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 34788517)

  • 21. Heparin-Induced Thrombocytopenia in COVID-19.
    Lingamaneni P; Gonakoti S; Moturi K; Vohra I; Zia M
    J Investig Med High Impact Case Rep; 2020; 8():2324709620944091. PubMed ID: 32720827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-Dose Prophylactic Anticoagulation in Severe COVID-19 Pneumonia.
    Nadeem R; Kamat S
    Chest; 2021 Jul; 160(1):e94-e95. PubMed ID: 34246406
    [No Abstract]   [Full Text] [Related]  

  • 23. Authors' reply.
    Koufakis T; Tsapakidis K; Margaritis A; Gabranis I
    J Postgrad Med; 2015; 61(4):268. PubMed ID: 26482023
    [No Abstract]   [Full Text] [Related]  

  • 24. COVID-19 in the Critically Ill: Too Risky for High-Dose Anticoagulation?
    Paez Vargas JJ; Vidal González A; Pérez-Calvo C; Flandes J
    Chest; 2021 Aug; 160(2):e249. PubMed ID: 34366058
    [No Abstract]   [Full Text] [Related]  

  • 25. The Effect of Anticoagulation Use on Mortality in COVID-19 Infection.
    Salah HM; Naser JA; Calcaterra G; Bassareo PP; Mehta JL
    Am J Cardiol; 2020 Nov; 134():155-157. PubMed ID: 32892991
    [No Abstract]   [Full Text] [Related]  

  • 26. In patients hospitalized with COVID-19, therapeutic- vs. prophylactic-dose heparin did not reduce a composite outcome at 28 d.
    Bikdeli B; Garcia DA
    Ann Intern Med; 2022 Feb; 175(2):JC16. PubMed ID: 35099997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparin-Induced Thrombocytopenia in Severe COVID-19.
    Daviet F; Guervilly C; Baldesi O; Bernard-Guervilly F; Pilarczyk E; Genin A; Lefebvre L; Forel JM; Papazian L; Camoin-Jau L
    Circulation; 2020 Nov; 142(19):1875-1877. PubMed ID: 32990022
    [No Abstract]   [Full Text] [Related]  

  • 28. Thromboelastography-Guided Management of Anticoagulated COVID-19 Patients to Prevent Hemorrhage.
    Stillson JE; Bunch CM; Gillespie L; Khan R; Wierman M; Pulvirenti J; Phyu H; Anderson S; Al-Fadhl M; Thomas AV; Kwaan HC; Moore E; Moore H; Walsh MM
    Semin Thromb Hemost; 2021 Jun; 47(4):442-446. PubMed ID: 33607668
    [No Abstract]   [Full Text] [Related]  

  • 29. Increased prevalence of heparin induced thrombocytopenia in COVID-19 patients.
    Preti PS; Russo M; Caneva L; Reduzzi M; Calabretta F; Spataro C; Grimaldi P; De Amici M; Testa G; Iotti GA; Mojoli F; Di Sabatino A
    Thromb Res; 2021 Jul; 203():33-35. PubMed ID: 33915353
    [No Abstract]   [Full Text] [Related]  

  • 30. Autoimmune heparin-induced thrombocytopenia: a rare manifestation of COVID-19.
    Julian K; Bucher D; Jain R
    BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 34031097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coagulation abnormalities and thrombosis in patients with COVID-19.
    Levi M; Thachil J; Iba T; Levy JH
    Lancet Haematol; 2020 Jun; 7(6):e438-e440. PubMed ID: 32407672
    [No Abstract]   [Full Text] [Related]  

  • 32. Another new application of heparin in COVID-19: more than anticoagulation and antiviral.
    Yu X
    J Investig Med; 2021 Aug; 69(6):1258. PubMed ID: 34112704
    [No Abstract]   [Full Text] [Related]  

  • 33. Quantitative measurement of heparin in comparison with conventional anticoagulation monitoring and the risk of thrombotic events in adults on extracorporeal membrane oxygenation.
    Chu DC; Abu-Samra AG; Baird GL; Devers C; Sweeney J; Levy MM; Muratore CS; Ventetuolo CE
    Intensive Care Med; 2015 Feb; 41(2):369-70. PubMed ID: 25465907
    [No Abstract]   [Full Text] [Related]  

  • 34. In non-critically ill patients with COVID-19, therapeutic anticoagulation improved survival to discharge without organ support.
    Donato AA
    Ann Intern Med; 2021 Dec; 174(12):JC134. PubMed ID: 34871053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence for increased circulating procoagulant phospholipids in patients with COVID-19 pneumonia and their prognostic role.
    Assimakopoulos SF; Emmanuil A; Tsimeka A; Chalkidi T; Marangos M; Gogos C
    Clin Chem Lab Med; 2020 Oct; 59(2):e53-e55. PubMed ID: 33112778
    [No Abstract]   [Full Text] [Related]  

  • 36. [Learning with COVID-19: what about anticoagulation?].
    Álvarez-Rodríguez E; González González R; Torres-Gárate R; López-Riquelme P; González Martil I; Abad Cuñado V
    An Sist Sanit Navar; 2020 Aug; 43(2):251-254. PubMed ID: 32865189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis and treatment of disseminated intravascular coagulation in COVID-19 patients: a scoping review.
    Mori H; Ohkawara H; Togawa R; Rikimaru M; Shibata Y; Ikezoe T
    Int J Hematol; 2021 Mar; 113(3):320-329. PubMed ID: 33550533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation.
    Takahashi W; Yoneda T; Koba H; Ueda T; Tsuji N; Ogawa H; Asakura H
    Int J Infect Dis; 2021 Jan; 102():529-531. PubMed ID: 33157292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review: anticoagulation for haemodialysis.
    Suranyi M; Chow JS
    Nephrology (Carlton); 2010 Jun; 15(4):386-92. PubMed ID: 20609088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Major bleeding complications in critically ill patients with COVID-19 pneumonia.
    Godier A; Clausse D; Meslin S; Bazine M; Lang E; Huche F; Cholley B; Hamada SR
    J Thromb Thrombolysis; 2021 Jul; 52(1):18-21. PubMed ID: 33646501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.